MGC Pharmaceuticals (ASX:MXC) has provided an update on its pre-clinical in vitro study of CimetrA.
CimetrA is the company's proprietary Investigation Medicinal Product.
The company said results from the study indicate that CimetrA may have a wider-ranging application as an anti-inflammatory treatment, beyond the treatment of the symptoms of COVID-19, which has been the primary focus of clinical trials to date.
The study undertaken by the Israeli contract research organisation, Science in Action, built on previous studies commissioned by MGC Pharma and examined the mechanism of CimetrA’s anti-inflammatory effect in Human Peripheral Blood Mononuclear Cells (PCBC).
The study found that CimetrA moderates the body’s release of pro-inflammatory cytokines.
Roby Zomer, co-founder and managing director of MGC Pharmaceuticals, said, “We have long had confidence in CimetrA, and this latest study on its mechanism of action highlights even more potential applications for the product. This is a big leap forward, with more conditions potentially being treatable with the drug.
"Its anti-inflammatory profile means that it could transform the lives of thousands of patients, and it is particularly reassuring that these latest results confirm the findings of previous studies. In light of these results, MGC is in the process of designing the next phase of CimetrA’s clinical pathway and will keep everyone updated.”